> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Takeda Recalls Natpara Over Rubber Particulates
- URL: https://www.fdaweb.com/takeda-recalls-natpara-over-rubber-particulates/
- Published: 2019-09-17T12:00:00.000Z
- Updated: 2026-09-15T01:50:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145016

Takeda Pharmaceutical Co. has recalled all doses of Natpara (parathyroid hormone) for injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg) due to a potential issue related to rubber particulates originating from the rubber septum of the product’s cartridge. During a typical 14-day Natpara treatment period, the septum is punctured by a needle each day to obtain the injectable dosage, a [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/takeda-issues-us-recall-natparar-parathyroid-hormone-injection-due-potential-rubber-particulate?ref=fdaweb.com) explains. “When the septum is repeatedly punctured, it is possible that small rubber fragments may detach into the cartridge,” it says. Natpara is a recombinant human protein approved for adjunctive treatment for adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone (calcium and vitamin D).